The combination of gemcitabine, cisplatin, and paclitaxel as salvage chemotherapy for advanced urothelial carcinoma

Takeshi Hirata, Masanori Hanamoto, Kazuma Ogura, Nobuki Hayashi, Kosuke Takamura, Kohei Edamura, Shin Ebara, Takashi Saika

Research output: Contribution to journalArticle

Abstract

There is no standard second-line or salvage treatment for advanced urothelial carcinoma (UC). Here we investigated the efficacy and safety of gemcitabine, cisplatin, and paclitaxel (GCP) combination chemotherapy as salvage chemotherapy for advanced UC. We retrospectively analyzed the cases of 23 patients with advanced UC who showed progression or recurrence after cisplatin-based chemotherapy. Gemcitabine (1000 mg/m2), and paclitaxel (80 mg/m2) were administered on days 1 and 8. Cisplatin (70 mg/m2) was administered on day 1. The 3-week cycle regimen was repeated until disease progression if it had no intolerable toxicity. The overall response rate was 61% (95%CI, 41-78%). The median overall survival and progression-free survival times were 14 months and 5.5 months, respectively. Of the already known risk factors of chemotherapy for advanced UC, only the performance status was a prognostic factor for OS. Overall, 16 of the 23 patients (70%) experienced grade 3/4 toxicities, and no fatal adverse events were observed. GCP therapy was a promising option as second- line or salvage therapy for advanced UC.

Original languageEnglish
Pages (from-to)175-179
Number of pages5
JournalActa Medica Okayama
Volume72
Issue number2
Publication statusPublished - Jan 1 2018
Externally publishedYes

Fingerprint

gemcitabine
Salvaging
Chemotherapy
Paclitaxel
Cisplatin
Carcinoma
Drug Therapy
Salvage Therapy
Toxicity
Combination Drug Therapy
Disease-Free Survival
Disease Progression
TP protocol
Safety
Recurrence
Survival

Keywords

  • Cisplatin
  • Gemcitabine
  • Paclitaxel
  • Salvage
  • Second-line
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Hirata, T., Hanamoto, M., Ogura, K., Hayashi, N., Takamura, K., Edamura, K., ... Saika, T. (2018). The combination of gemcitabine, cisplatin, and paclitaxel as salvage chemotherapy for advanced urothelial carcinoma. Acta Medica Okayama, 72(2), 175-179.

The combination of gemcitabine, cisplatin, and paclitaxel as salvage chemotherapy for advanced urothelial carcinoma. / Hirata, Takeshi; Hanamoto, Masanori; Ogura, Kazuma; Hayashi, Nobuki; Takamura, Kosuke; Edamura, Kohei; Ebara, Shin; Saika, Takashi.

In: Acta Medica Okayama, Vol. 72, No. 2, 01.01.2018, p. 175-179.

Research output: Contribution to journalArticle

Hirata, T, Hanamoto, M, Ogura, K, Hayashi, N, Takamura, K, Edamura, K, Ebara, S & Saika, T 2018, 'The combination of gemcitabine, cisplatin, and paclitaxel as salvage chemotherapy for advanced urothelial carcinoma', Acta Medica Okayama, vol. 72, no. 2, pp. 175-179.
Hirata, Takeshi ; Hanamoto, Masanori ; Ogura, Kazuma ; Hayashi, Nobuki ; Takamura, Kosuke ; Edamura, Kohei ; Ebara, Shin ; Saika, Takashi. / The combination of gemcitabine, cisplatin, and paclitaxel as salvage chemotherapy for advanced urothelial carcinoma. In: Acta Medica Okayama. 2018 ; Vol. 72, No. 2. pp. 175-179.
@article{810813f1953146c38d4c1035663700e5,
title = "The combination of gemcitabine, cisplatin, and paclitaxel as salvage chemotherapy for advanced urothelial carcinoma",
abstract = "There is no standard second-line or salvage treatment for advanced urothelial carcinoma (UC). Here we investigated the efficacy and safety of gemcitabine, cisplatin, and paclitaxel (GCP) combination chemotherapy as salvage chemotherapy for advanced UC. We retrospectively analyzed the cases of 23 patients with advanced UC who showed progression or recurrence after cisplatin-based chemotherapy. Gemcitabine (1000 mg/m2), and paclitaxel (80 mg/m2) were administered on days 1 and 8. Cisplatin (70 mg/m2) was administered on day 1. The 3-week cycle regimen was repeated until disease progression if it had no intolerable toxicity. The overall response rate was 61{\%} (95{\%}CI, 41-78{\%}). The median overall survival and progression-free survival times were 14 months and 5.5 months, respectively. Of the already known risk factors of chemotherapy for advanced UC, only the performance status was a prognostic factor for OS. Overall, 16 of the 23 patients (70{\%}) experienced grade 3/4 toxicities, and no fatal adverse events were observed. GCP therapy was a promising option as second- line or salvage therapy for advanced UC.",
keywords = "Cisplatin, Gemcitabine, Paclitaxel, Salvage, Second-line, Urothelial carcinoma",
author = "Takeshi Hirata and Masanori Hanamoto and Kazuma Ogura and Nobuki Hayashi and Kosuke Takamura and Kohei Edamura and Shin Ebara and Takashi Saika",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "72",
pages = "175--179",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "2",

}

TY - JOUR

T1 - The combination of gemcitabine, cisplatin, and paclitaxel as salvage chemotherapy for advanced urothelial carcinoma

AU - Hirata, Takeshi

AU - Hanamoto, Masanori

AU - Ogura, Kazuma

AU - Hayashi, Nobuki

AU - Takamura, Kosuke

AU - Edamura, Kohei

AU - Ebara, Shin

AU - Saika, Takashi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - There is no standard second-line or salvage treatment for advanced urothelial carcinoma (UC). Here we investigated the efficacy and safety of gemcitabine, cisplatin, and paclitaxel (GCP) combination chemotherapy as salvage chemotherapy for advanced UC. We retrospectively analyzed the cases of 23 patients with advanced UC who showed progression or recurrence after cisplatin-based chemotherapy. Gemcitabine (1000 mg/m2), and paclitaxel (80 mg/m2) were administered on days 1 and 8. Cisplatin (70 mg/m2) was administered on day 1. The 3-week cycle regimen was repeated until disease progression if it had no intolerable toxicity. The overall response rate was 61% (95%CI, 41-78%). The median overall survival and progression-free survival times were 14 months and 5.5 months, respectively. Of the already known risk factors of chemotherapy for advanced UC, only the performance status was a prognostic factor for OS. Overall, 16 of the 23 patients (70%) experienced grade 3/4 toxicities, and no fatal adverse events were observed. GCP therapy was a promising option as second- line or salvage therapy for advanced UC.

AB - There is no standard second-line or salvage treatment for advanced urothelial carcinoma (UC). Here we investigated the efficacy and safety of gemcitabine, cisplatin, and paclitaxel (GCP) combination chemotherapy as salvage chemotherapy for advanced UC. We retrospectively analyzed the cases of 23 patients with advanced UC who showed progression or recurrence after cisplatin-based chemotherapy. Gemcitabine (1000 mg/m2), and paclitaxel (80 mg/m2) were administered on days 1 and 8. Cisplatin (70 mg/m2) was administered on day 1. The 3-week cycle regimen was repeated until disease progression if it had no intolerable toxicity. The overall response rate was 61% (95%CI, 41-78%). The median overall survival and progression-free survival times were 14 months and 5.5 months, respectively. Of the already known risk factors of chemotherapy for advanced UC, only the performance status was a prognostic factor for OS. Overall, 16 of the 23 patients (70%) experienced grade 3/4 toxicities, and no fatal adverse events were observed. GCP therapy was a promising option as second- line or salvage therapy for advanced UC.

KW - Cisplatin

KW - Gemcitabine

KW - Paclitaxel

KW - Salvage

KW - Second-line

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85047179936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047179936&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 175

EP - 179

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 2

ER -